A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Trial Profile

A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Aflibercept
  • Indications Age-related macular degeneration; Blindness
  • Focus Therapeutic Use
  • Acronyms SALT
  • Sponsors Novartis
  • Most Recent Events

    • 31 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jul 2017 This trial has been completed in Sweden (end date: 2017-05-29).
    • 09 Jul 2017 This trial has been completed in Denmark (end date: 2017-05-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top